Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of QX005N in adult prurigo nodularis
ChiCTR2300073171Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QX005N in prurigo nodularis (PN), sponsored by Peking University People's Hospital. Primary endpoint: Adverse events (AEs). Planned start Jul 2023; status: not yet recruiting.
02
Drugs
QX005N
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on ChiCTR2300073171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073171.